Prof Garot from Massy Hospital has enrolled the first patient in the SCOPE II (Safety and efficacy Comparison Of two TAVI in an Prospective randomized Evaluation II: A randomized controlled non-inferiority trial evaluating early safety and clinical efficacy of the Symetis ACURATE NEo compared to the Medtronic Evolut R bioprosthesis in transfemoral transcatheter aortic valve implantation.) study.
